Weekly methotrexate (50 mg/m2) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 477-480

  Kang, Woo Dae ^a   Choi, Ho Sun ^a   Kim, Seok Mo ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Gestational trophoblastic neoplasia; Low risk; Methotrexate; Single agent chemotherapy

Indexed keywords

CHORIONIC GONADOTROPIN; DACTINOMYCIN; FOLINIC ACID; METHOTREXATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ALOPECIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REMISSION; RISK; SCORING SYSTEM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TROPHOBLASTIC TUMOR; CANCER STAGING; DRUG ADMINISTRATION; PATHOLOGY; PREGNANCY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; LEUCOVORIN; METHOTREXATE; NEOPLASM STAGING; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77951938882     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.02.029     Document Type: Article

References (16)

1. Foulmann K., Guastalla J.P., Caminet N., Trillet-Lenoir V., Raudrant D., Golfier F., et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 102 1 (2006) 103-110
2. Kohorn E.I. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med 47 (2002) 445-450
3. Li M.C., Hertz R., and Spencer D.B. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93 (1956) 361-366
4. Bagshawe K.D., Dent J., Newlands E.S., Begent R.H., and Rustin G.J. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 96 7 (1989) 795-802
5. McNeish I.A., Strickland S., Holden L., Rustin G.J., Foskett M., Seckl M.J., et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 20 7 (2002) 1838-1844
6. Homesley H.D., Blessing J.A., Rettenmaier M., Capizzi R.L., Major F.J., and Twiggs L.B. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 72 (1988) 413-418
7. Kohorn E.I. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 11 (2001) 73-77
8. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), March 31, 2003. Available at http://ctep.cancer.gov.
9. Khan F., Everard J., Ahmed S., Coleman R.E., Aitken M., and Hancock B.W. Low-risk persistent trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long term effects. Br J Cancer 89 12 (2003) 2197-2201
10. Homesley H.D., Blessing J.A., Schlaerth J., Rettenmaier M., and Major F.J. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecol Oncol 39 (1990) 305-308
11. Gleeson N.C., Finan M.A., Fiorica J.V., Robert W.S., Hoffman M.S., and Wilson J. Gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 14 6 (1993) 461-465
12. Gilani M.M., Yarandi F., Eftekhar Z., and Hanjani P. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol 45 2 (2005) 161-164
13. Yarandi F., Eftekhar Z., Shojaei H., Kanani S., Sharifi A., and Hanjani P. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet 103 1 (2008) 33-37
14. Mohit M., Sarraf Z., Sheikhi G., Robati M., and Vasheghani-Farahani A. Weekly intramuscular methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Arch Gynecol Obstet 280 5 (2009) 775-780
15. Lertkhachonsuk A.A., Israngura N., Wilailak S., and Tangtrakul S. Actinomycin D versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer 19 5 (2009) 985-988
16. Chalouhi G.E., Golfier F., Soignon P., Massardier J., Guastalla J.P., Trillet-Lenoir V., et al. Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol 200 6 (2009) 643.e1-6